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ABSTRACT
Punch biopsies are a widely used diagnostic method in veterinary dermatology. During a biopsy, it is 
necessary to use local anesthesia and/or sedation to prevent pain. Lidocaine is a local analgesic drug that is 
often used. Adding adrenaline to lidocaine solutions for local anesthesia potentiates and prolongs its analgesic 
action. Intravenous lidocaine administration has been reported to cause signifi cant side effects, seizures being 
considered the most common sign of intoxication, while bradyarrhythmia and conduction disturbances are less 
prevalent. The aim of this study is to investigate the potential lidocaine toxicity effect of two frequently used 
local anesthetic solutions, lidocaine and lidocaine/adrenaline combination. Nine healthy dogs were randomly 
assigned into two groups. One group (n = 4) received subcutaneous injections of lidocaine (total of six 1 mL 
injections of 2 % lidocaine solution), while the dogs in the second group (n = 5) received a lidocaine/adrenaline 
combination (total of six 1 mL injections of 2 % lidocaine solution plus 0.0125 mg adrenaline tartarate). None 
of the known lidocaine side effects were observed. The blood concentration of lidocaine was far below the 
reported convulsive threshold in dogs. Subcutaneous administration of two different lidocaine local anesthetic 
formulations was shown to be well tolerated and safe. This research suggests that lidocaine and lidocaine/
adrenaline formulation can be safely used as a local anesthetic for skin punch biopsies in dogs with body mass 
greater than 5 kg. 
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Introduction 
Skin biopsy techniques have been widely used as a diagnostic method in veterinary 
dermatology, particularly when dealing with an unfamiliar clinical presentation or a case 
that progresses or relapses despite seemingly appropriate empirical therapy (YAGER 
and WILCOCK, 1988). The simplest and quickest method of skin biopsy involves the use 
of a punch biopsy technique (HENFREY et al., 1991; CURTIS, 2001), during which it is 
necessary to use subcutaneous injections of local anesthetics and/or sedation to control 
pain in dogs (SKARDA, 1998).
Lidocaine is a local anesthetic, which, due to its rapid onset of action, low cost and 
wide availability, is commonly used, in veterinary dermatology. It is applied in a variety 
of ways; topically (by local subcutaneous infi ltration, epidural injection, nerve block) or 
by intravenous injection into a peripheral vein to provide limb analgesia (DUKE, 2000). 
Lidocaine also has an anti-arrhythmic effect, being sometimes used for the acute control 
of life-threatening ventricular arrhythmia in dogs and cats (LUNNEY and ETTINGER, 
1995). Furthermore, intravenous lidocaine administration has been reported to cause 
signifi cant side effects (WILCKE et al., 1983; LUNNEY and ETTINGER, 1995); seizures 
being considered the most common sign of intoxication, while bradyarrhythmia and 
conduction disturbances are less prevalent (WILCKE et al., 1983; LUNNEY and ETTINGER, 
1995). Adrenaline is commonly co-administered with lidocaine in some local anesthetic 
formulations. Adding adrenaline to lidocaine diminishes local blood fl ow and therefore 
lidocaine clearance (SCOTT et al., 1972; SINNOTT et al., 2003), prolonging lidocaine’s action 
in a dose-related manner (LIU et al., 1995). In addition, the higher pH of the lidocaine-
adrenaline solution could reduce pain on injection in humans (COLARIC et al., 1998).
Recently, seizures occurred in two dogs with body mass of less than 5 kilograms (kg) 
in association with the administration of subcutaneous lidocaine and intravenous sedative 
medetomidine for the purpose of acquiring several skin punch biopsies (RAINGER et 
al., 2009). The authors recommended not to exceed the toxic lidocaine dose of 11 mg/
kg in dogs for local anesthesia due to possible side effects (RAINGER et al., 2009). To the 
author’s knowledge, there are no studies describing the potential systemic toxicity of 
subcutaneous lidocaine injections provided for skin biopsies in dogs.
The primary objective of this noninvasive study was to investigate the potential 
lidocaine toxicity effect of two frequently used local anesthetic solutions, lidocaine and 
lidocaine/adrenaline, provided for punch skin biopsy procedure in dogs with body mass 
higher than 5 kg. The second aim of this study was to compare the clinical toxic effects 
and systemic lidocaine absorption after administration of these two local anesthetics.
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Materials and methods
The study protocol was approved by the Research Committee of the Faculty of 
Veterinary Medicine, University of Zagreb, and followed the national legislation on 
the care and use of laboratory animals. Written informed consent was obtained from 
each owner. The methodology in this study followed the skin biopsy punch technique 
recommended for veterinary practitioners (HENFREY et al., 1991; CURTIS, 2001).
Nine healthy dogs (6 males and 3 females) older than 3 months, with a minimum mass 
of 5 kilograms that presented to the Clinic for Internal Medicine, Faculty of Veterinary 
Medicine, University of Zagreb, were randomly assigned via a computer-generated list, 
into two groups. One group received subcutaneous injections of lidocaine (group L; n = 
4), while the dogs in the second group were given a lidocaine/adrenaline combination 
(group L+A; n = 5). Clinical examination and basic laboratory work (hematology and 
biochemistry panel), performed on all dogs before entering the study, revealed no 
abnormalities. No oral and/or topical medications were permitted to be given to any dog 
4 weeks prior to inclusion in the study. 
Following the recommendation to collect a minimum of 5 punch biopsies from each 
dog to ensure that the samples actually represent the pathogenic process in question 
(LINDER, 2001), three symmetrical cutaneous body sites per each dog (total of 6 skin 
punch sites) were selected for the skin punch biopsy procedure, using a disposable 
sterile 8-mm biopsy punch. The sites were gentle clipped and outlined with a marker 
pen before administration of the local anesthesia. Each selected symmetrical body site 
(scapula region, the lower level of last rib, and loins) was undermined with 1 milliliter 
(mL) of the appropriate local anesthetic, according to the study randomization, injected 
subcutaneously through a 2 mL syringe with a 25-gauge needle. Each dog in group L 
received a total of six 1 mL injections of 2 % lidocaine solution (Lidokain 2 %, Belupo, 
HR; 1 mL contains 20 milligrams (mg) of lidocaine), while each animal in group L+A 
was given a different anesthetic solution that contained additional adrenaline (Lidokain-
adrenalin, Belupo, HR; 1mL contains 20 mg lidocaine and 0.0125 mg adrenaline tartarate). 
After a local anesthesia injection, it is recommended to allow enough time, usually 5 
minutes, for the lidocaine to reach full effect before beginning the procedure with the 
biopsy punch. The act of performing the full-thickness skin punch and acquiring the skin 
biopsy specimen was not deemed necessary for the objectives of this study. 
As soon as the dogs were locally anaesthetized, the time of the procedure was 
noted as time 0. Any potential adverse toxic clinical effects due to the administration 
of anesthetic lidocaine (WILCKE et al., 1983; LUNNEY and ETTINGER, 1995; RAINGER 
et al., 2009) (i.e. tremors, convulsion, and myoclonic movements) were recorded during 
the entire observation time, from 0 to 120 minutes. An intravenous catheter (20, 22 or 
24 G depending on the size of the dog) was inserted into the cephalic vein, and a 3.5 
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milliliter (mL) blood sample was collected, in accordance with the following schedule: 
before application of local anesthetic injections (0 minutes) and after 10 minutes, 30 
minutes, 60 minutes, 90 minutes and 120 minutes. The blood samples were centrifuged 
(3000/min) to collect the serum. Serum lidocaine concentrations were measured by gas 
chromatography-mass spectrometry as previously described (LEMO et al., 2007)
For statistical evaluation, STATISTICA 7.0 (StatSoft Inc., Tulsa, OK, USA) was 
used. The differences in the type of treatment (lidocaine or lidocaine+adrenaline) at the 
same time points were assessed by the Mann-Whitney U test and the differences between 
each pair of groups at different time points by the Newman-Keuls test. The infl uence of 
predictor variables, such as gender, mass, age and type of treatment, on the lidocaine 
serum concentration time was assessed by the general regression model, and the results 
were expressed as Pareto charts of t-values. A P-value of <0.05 was considered signifi cant.
Results
The signalment and lidocaine dosage data for the 9 dogs included in the study are 
summarized in Table 1. 










Dog 1 Group L Mixed breed 60 F 13.5 8.8
Dog 2 Group L Mixed breed 54 F 19.0 6.3
Dog 3 Group L Alaskan malamute 72 M 52.0 2.3
Dog 4 Group L Golden Retriever 84 M 48.0 2.5
Dog 5 Group L+A Poodle 168 M 10.7 11.2
Dog 6 Group L+A Mixed breed 36 M 18.0 6.6
Dog 7 Group L+A Mixed breed 36 F 8.0 15.0
Dog 8 Group L+A Boxer 120 M 26.5 4.5
Dog 9 Group L+A Mixed breed 12 M 32.0 3.75
L, lidocaine; L+A, lidocaine plus adrenaline; M, male; F, female; mg, milligram; kg, kilogram
No signifi cant differences in body mass existed between the two groups (33.1 ± 19.6 
kg for the lidocaine-treated dogs vs. 20.8 ± 10.1 kg for the lidocaine plus adrenaline 
treated dogs; P = 0.26). The mean lidocaine dose given to dogs in Group L was 4.9 mg/
kg (range 2.5 - 8.8 mg/kg) while the mean lidocaine dose for Group L+A was 8.2 mg/
kg (range 3.75 - 15 mg/kg). None of the known lidocaine side effects, such as tremors, 
convulsions or myoclonic movements, or any other abnormalities were observed in any 
dog during the follow up of 120 minutes after the subcutaneous anesthetic administrations. 
The highest mean value of serum lidocaine concentration in Group L was observed 30 
minutes after administration (0.48 μg/mL) while the lowest concentration was measured 
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after 10 minutes (0.27 μg/mL) (Fig. 1). At 120 minutes, the mean serum lidocaine level 
in Group L was 0.35 μg/mL. In the presence of adrenaline (Group L+A), serum lidocaine 
concentrations increased linearly, reaching a peak concentration after 60 minutes of 
exposure (mean value of 0.72 μg/mL) and then decreased slightly over the following 60 
minutes, reaching a mean value of 0.53 μg/mL at 120 minutes after administration (Fig. 1). 
Fig. 1. Box and whisker plot of the lidocaine serum concentrations in micrograms/microliter (μg/
mL) in the dogs treated with lidocaine in the absence (L) or presence (L+A) of adrenaline for 
exposure periods from 10 to 120 minutes
With the exception of the 10-minute exposure period, lidocaine serum levels 
were higher in the presence of adrenaline (Group L+A) for all exposure times; the 
highest difference in the mean values was observed at 60 minutes after the anesthetic 
administrations. No statistical signifi cance was observed using the Man-Whitney U test 
between the two types of the treatments, comparing exposure periods at 10 minutes (P 
= 0.66), 30 minutes (P = 0.83), 60 minutes (P = 0.52), 90 minutes (P = 0.88) and 120 
minutes (P = 0.56). Furthermore, there was no signifi cant difference observed between 
different time periods for any tested pairs of the groups according to the Newman-Keuls 
test. The Pareto charts of t values of the predictor variables for each exposure period are 
presented in Fig. 2. Selected predictor variables (age, gender, mass and type of treatment) 
had the lowest infl uence at 10 and 120 minutes of exposure to lidocaine in the presence/
absence of adrenaline (Fig. 2). However, the results of the general regression model 
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Discussion 
Lidocaine is one of the most widely used local anesthetic agents in veterinary practice, 
with a mechanism of action targeting the cell membrane, thereby preventing the generation 
and the conduction of nerve impulses. Despite the apparent safety of lidocaine, there are a 







































Fig. 2. Pareto charts of t values of the predictor variables (age, gender, mass, treatment) for each 
exposure period (10, 30, 60, 90, 120 minutes) 
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2004; MORAN et al., 2004; ALFANO et al., 1984). The most common toxic reaction from 
lidocaine is excitation of the central nervous system (i.e. drowsiness, dizziness, agitation, 
seizures) (SKARDA, 1998). Toxic reactions from subcutaneous injections occur later, 
because the peak time for subcutaneous absorption is 15 to 30 minutes, depending on 
the anatomic location and the use of adrenaline (SCOTT et al., 1972). In human medical 
literature, it was suggested that the subcutaneous lidocaine dosage should be limited to 
4.5 mg/kg or 7 mg/kg when used with or without the vasoconstrictor adrenaline (ALFANO 
et al., 1984; RYAN et al., 1993). Importantly, these lidocaine dosage recommendations were 
not substantiated by any detailed studies correlating lidocaine serum concentrations after 
subcutaneous injections and toxic effects. 
In this report, we determined the serum lidocaine concentrations, with no lidocaine 
associated toxic effects, from two different lidocaine formulations, for the purpose of 
subcutaneous local anesthesia in canine skin biopsies. In our study, none of the dogs 
experienced any known lidocaine side effects, such as tremors, convulsions or myoclonic 
movements. Furthermore, the blood concentration of lidocaine in our study was far 
below the reported convulsive threshold in dogs (47 μg/mL) after intravenous lidocaine 
administration (FELDMAN et al., 1989); the highest serum concentration of lidocaine was 
0.76 μg/mL for Group L (dog 1 at 30 minutes) and 1.73 μg/mL for Group L+A (dog 9 at 
60 minutes), respectively. However, seizures in people have been associated with plasma 
lidocaine levels between 5 and 15 μg/mL (ALFANO et al., 1984; AHMED et al., 2004) and 
in one dog with a lidocaine level of 2.3 μg/mL (RAINGER et al., 2009). These particularly 
sensitive individuals likely have an abnormal metabolism and high plasma levels of the 
lidocaine metabolites monoethylglycinexilidide and 2.6-glycine xylide, which may be 
responsible for seizure side effects (DE TOLEDO, 2000).
Lidocaine levels can be affected by several factors, such as drug interactions, hepatic 
metabolism and even the site of injections, due to possible increased vascularity in 
certain body areas. Furthermore, lidocaine levels can be infl uenced by using adrenaline in 
combination with lidocaine, where local vasoconstriction from the adrenaline delays the 
absorption of lidocaine. The maximum serum lidocaine levels in Group L were achieved 
after 30 minutes, which is in accordance within human studies, while in Group L+A the 
peak was delayed for another 30 minutes (maximum level at 60 minutes) confi rming the 
effect of adrenaline on lidocaine systemic absorption (SCOTT et al., 1972).
There are only rare reports of lidocaine-associated toxicity in veterinary patients after 
subcutaneous lidocaine injections for acquiring skin biopsy specimens. A recent report 
suggested that the total lidocaine volume administered in dogs should not exceed 11 mg/kg. 
In situations where higher dosages of lidocaine are needed (multiple skin biopsy sites per 
dog), the authors recommend using lower volumes of local anesthetics while performing 
skin biopsy under general anesthesia (RAINGER et al., 2009). However, the maximum 
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lidocaine dose of 11 mg/kg per dog was actually extrapolated from the convulsive toxic 
dose of intravenously administered lidocaine in conscious dogs (SKARDA, 1998), which 
does not equal subcutaneous administration, as the pharmacokinetics of lidocaine differ 
signifi cantly depending on the route of administration (SCOTT et al., 1972). In this report, 
two dogs (dog 7 and 9) were administered a total lidocaine volume of more than 11 mg/
kg with no adverse toxic side effects observed during 120 minutes post-administration. 
There are some limitations to this study. First, sedative agents, such as α2-adrenergic 
agonis and, medetomidine, were used during skin biopsy procedures in some patients. 
This agent may potentiate the neurological effects of lidocaine, although supporting 
evidence is rare (RAINGER et al., 2009). No sedative agents were used in any dog during 
our study, which may lead to underestimating seizure occurrence in a clinical practice 
setting when medetomidine is additionally used for skin biopsy procedures. Second, only 
dogs with body mass greater than 5 kg were included in the study, so caution must be 
used when trying to extrapolate this lidocaine safety information for dogs with lower 
body mass (<5 kg). 
In conclusion, subcutaneous administration of two different lidocaine local anesthetic 
formulations at 6 body sites per dog was shown to be well tolerated and safe in 9 dogs. 
Total lidocaine volume of up to 15 mg/kg subcutaneously injected did not cause any 
adverse toxic side effects, however, studies of its use for skin biopsies in dogs with lower 
body mass (<5 kg) and in conjunction with α2-adrenergic agonist medetomidine are 
needed to assess a lidocaine full toxicity panel. This research suggests that lidocaine and 
lidocaine/adrenaline formulation can be safely used as a local anesthetic for skin punch 
biopsies in dogs with body mass greater than 5 kg. 
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SAŽETAK
Biopsija kože naširoko se primjenjuje kao dijagnostička metoda u veterinarskoj dermatologiji. Tijekom 
biopsije, potrebno je primijeniti lokalnu anesteziju i/ili sedaciju za sprečavanje boli. Lidokain je lokalni analgetik 
koji se često primjenjuje. Dodavanjem adrenalina uz lidokain pojačava se i produljuje analgetsko djelovanje. 
Intravenska primjena lidokaina u nekim je slučajevima pokazala značajne nuzučinke. Napadaj drhtavice smatra 
se najčešćim znakom intoksikacije, a bradiaritmija i smetnje u provođenju su rjeđe opisani nuzučinci. Cilj je 
ovog rada istražiti potencijalnu toksičnost lidokaina u dvije često primjenjivane lokalne anestezije: lidokain i 
lidokain/adrenalin kombinacija. Devet zdravih pasa nasumično su bili podijeljeni u dvije skupine. Jedna skupina 
(n = 4) primila je potkožne injekcije anestetika (ukupno šest injekcija od 1 mL s 2%-tnom lidokain otopinom), 
dok su psi u drugoj skupini (n = 5) primali lidokain/adrenalin kombinaciju (ukupno šest injekcija od 1 mL 2%-
tnog lidokaina s 0,0125 mg adrenalin tartarata). Niti jedan od poznatih lidokainskih nuzučinaka nije zabilježen 
pri istraživanju. Koncentracija lidokaina u krvi daleko je ispod prijavljenog praga toksičnosti u pasa. Potkožna 
primjena dviju različitih anestetičkih formulacija pokazala se dobrom i sigurnom. Ovo istraživanje upućuje na 
zaključak da se lidokain i lidokain/adrenalin formulacije mogu sigurno primjenjivati kao lokalni anestetici pri 
biopsiji kože kod psa s tjelesnim težinama većim od 5 kilograma. 
Ključne riječi: lidokain, adrenalin, toksičnost, biopsija kože, serumska koncetracija________________________________________________________________________________________
